NLRP3 inflammasome

Blocking the activity of a protein complex called the NLRP3 inflammasome lessened disease severity in a mouse model of multiple sclerosis (MS), a study reports. Results point to NLRP3 as a promising target to ease inflammation in people with MS, but additional studies will be needed to determine the…

Dr. Rebecca Coll, a young researcher at the University of Queensland Institute of Molecular Bioscience, won the 2016 Research Australia Discovery Award for her work in identifying promising anti-inflammatory compounds that are able to block the NLRP3 inflammasome — a key driver of inflammation. The discovery could greatly benefit patients with inflammatory diseases,…

In multiple sclerosis (MS) patients who do not respond to interferon-beta treatment, autoimmunity may depend on processes that differ from patients helped by this treatment— a finding that could lead both to better therapies and tests that predict a patient’s likely response. The study, “An interferon-β-resistant and NLRP3…

Multiple Sclerosis News Today has reported the latest therapies, clinical trial developments, and events in multiple sclerosis (MS) on a daily basis throughout the past year. As 2015 comes to an end, here are the year’s 10 articles most widely read by  Multiple Sclerosis News Today readers, each with a brief summary of the developments…

In a new study, researchers at UT Southwestern Medical Center in Texas and The Scripps Research Institute in California discovered that the enzyme NEK7, vital to cell division, plays a crucial role in the activation of the NLRP3 inflammasome, essential to the onset of inflammation. This discovery may have a significant impact…

A newly discovered molecule could play a pivotal role in inflammatory diseases, including multiple sclerosis, according to researchers at Trinity College Dublin and the University of Queensland Australia. The study was published in the journal Nature Medicine, and describes a molecule known as MCC950 that can suppress the ‘NLRP3 inflammasome’,…